Valneva debuts UK commercial operations

23 March 2016

French biotech firm Valneva (Euronext: VLA), a leading pure play vaccine company, has now established a commercial operation in the UK. The company already has a manufacturing site in Livingston, Scotland.

Valneva manufactures and markets two vaccines: Dukoral, which helps provide oral protection against cholera; and Ixiaro, which helps to protect against Japanese encephalitis. Both these vaccines are the only products licensed and recommended for active immunization against their respective diseases in the UK.

Travel health in the UK presents a number of challenges, with only 50% of travellers seeking adviceand many people travelling unprotected. Valneva UK aims to work in partnership with healthcare professionals to improve the provision of travel health services in the UK.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK